Pune, Maharashtra -- (SBWIRE) -- 04/10/2017 -- Market Highlights
Hepatitis C is caused by infection by hepatitis C virus and is characterized by yellowed eyes and skin due to bilirubin, flu-like symptoms which include nausea, vomiting, poor appetite, joint pain, headaches, clay colored stools etc. Unlike other forms of hepatitis, there is no vaccine for hepatitis and the disease claims a global toll of 700000 lives annually of the 130–150 million people it infects.
The factors driving the global hepatitis C market are disease prevalence, rise in government subsidy and reimbursement especially in U.S., greater screening especially in developing nations, drug abuse and unsafe sex etc. The market constraints are self-imitating nature of the disease in a sizable number of patients, challenge of herbal treatment offered at negligible prices especially in developing regions, price war between companies such as between Gilead and Merck, rising urbanization and better sanitation etc. The rising cure rates and the falling number of patients have stagnated the developed regions market and the market may take a negative turn. The apprehensions of large players about the advent of vaccine have numbed the research pipeline for other drug classes.
Request a Sample Report@ https://www.marketresearchfuture.com/sample_request/2487
Global Hepatitis C drugs market:
The global Hepatitis C drugs market has been evaluated as a slowly growing market and it is expected that the market will touch flat growth figures in future. The global Hepatitis C drugs market is expected to grow with CAGR of ~3.3% during the forecast period. The market is dominated by large players and a few molecules. The loss of patents on these few molecules represents a major threat to the future growth of the global hepatitis C market. The market is hungry for a complete cure of hepatitis C as happened to other forms of hepatitis.
The major participants of this market are: Gilead sciences Inc., Abbvie Inc, Johnson & Johnson, Merck & co. Inc., Glaxosmithkline plc, Novartis AG, Bristol-Myers Squibb, Hoffmann-la Roche ltd. and others.
Regional Analysis:
Depending on geographic region, Hepatitis C drugs market is segmented into four key regions: America, Europe, Asia Pacific, and Middle East & Africa. Globally, America is the largest market for Hepatitis C drugs followed by Europe. The market for these developed regions will remain stagnant and the Asia Pacific region may become the top market in the near future due to its faster rate of growth. The African region is expected to be a laggard.
Key Players
Gilead sciences Inc., Abbvie Inc, Johnson & Johnson, Merck & co. Inc., Glaxosmithkline plc, Novartis AG, Bristol-Myers Squibb, Hoffmann-la Roche ltd. and others.
Segmentation
By Drug Class Anti-Viral, Immuno-modulators and others
By Medicine System Allopathic, Alternative and Others
By Route of Administration Oral, Injectable and others
By End User (Hospitals and Private
By Region - North America, Europe, Asia-Pacific and ROW
Test the market data and market information presented through more than 60 market data tables and figures spread over 84 numbers of pages of the project report. Avail the in-depth table of content (TOC) & market synopsis on "The Global Hepatitis C Drugs Market Research Report - Forecast to 2022".
List of Tables
Table 1 Global Sterilized Packaging Market, By Material
Table 2 Global Sterilized Packaging Market, By Type
Table 3 Global Sterilized Packaging Market, By Regions
Table 4 North America Sterilized Packaging Market, By Material
Table 5 North America Sterilized Packaging Market, By Type
Table 6 U.S. Sterilized Packaging Market, By Material
Table 7 U.S. Sterilized Packaging Market, By Type
Table 8 Canada Sterilized Packaging Market, By Material
Table 9 Canada Sterilized Packaging Market, By Type
Browse Full H-C-D Market @ https://www.marketresearchfuture.com/reports/hepatitis-c-drugs-market-2487
Table of Content
1Introduction
3Market Dynamics
3.1Drivers
3.2Restraints
4Market Factor Analysis
5Global Hepatitis C Drugs market, by Drug Class
5.1Introduction
5.2Anti-Viral
5.3Immuno-modulators
6Global Hepatitis C Drugs Market, By Medicine System
6.1Introduction
6.2Allopathic
6.3Alternative
7Global Hepatitis C Drugs Market, By Route of Administration
7.1Introduction
7.2Oral
7.3Injectable
8Global Hepatitis C Drugs Market, By End User
8.1Introduction
8.2Hospitals
8.3Private
9Global Hepatitis C Drugs market, by Regions
10Company Landscape
11Company Profile
About Market Research Future
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact:
Akash Anand
Market Research Future
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
646-845-9312
Email: akash.anand@marketresearchfuture.com
Web: https://www.marketresearchfuture.com